Get the Stockscreener App
68.50
2.59%
1.73
After Hours:
68.50
Apogee Therapeutics Inc stock is traded at $68.50, with a volume of 645.55K.
It is up +2.59% in the last 24 hours and down -0.62% over the past month.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
See More
Previous Close:
$66.77
Open:
$66.54
24h Volume:
645.55K
Relative Volume:
0.68
Market Cap:
$4.72B
Revenue:
-
Net Income/Loss:
$-255.84M
P/E Ratio:
-16.25
EPS:
-4.2149
Net Cash Flow:
$-232.60M
1W Performance:
-6.82%
1M Performance:
-0.62%
6M Performance:
+87.52%
1Y Performance:
+69.39%
1-Day Range:
$66.01
$69.59
1-Week Range:
$66.01
$76.27
52-Week Range:
$26.20
$84.56
Apogee Therapeutics Inc Stock (APGE) Company Profile
Name
Apogee Therapeutics Inc
Sector
Industry
Phone
650-394-5230
Address
221 CRESCENT ST., WALTHAM
Compare APGE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
68.50 | 4.60B | 0 | -255.84M | -232.60M | -4.2149 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Initiated | Truist | Hold |
| Jan-22-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-07-26 | Initiated | Wolfe Research | Peer Perform |
| Dec-17-25 | Initiated | Stephens | Overweight |
| Dec-10-25 | Initiated | Deutsche Bank | Buy |
| Nov-03-25 | Initiated | Craig Hallum | Buy |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Sep-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-07-25 | Reiterated | BTIG Research | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Nov-25-24 | Initiated | Canaccord Genuity | Buy |
| May-10-24 | Initiated | BofA Securities | Buy |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | Guggenheim | Buy |
| Aug-08-23 | Initiated | Jefferies | Buy |
| Aug-08-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
| Aug-08-23 | Initiated | Wedbush | Outperform |
View All
Apogee Therapeutics Inc Stock (APGE) Latest News
This Xponential Fitness Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Benzinga
This Rocket Lab Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
This Union Pacific Analyst Turns Bullish; Here Are Top 3 Upgrades For Wednesday - Benzinga
This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Apogee Therapeutics Inc. (NASDAQ:APGE) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Truist initiates Apogee Therapeutics stock with Hold on high bar - Investing.com
Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics (APGE), Wave Life Sciences (WVE) and Telix Pharmaceuticals (OtherTLPPF) - The Globe and Mail
Aug Spikes: Is Apogee Therapeutics Inc backed by strong institutional buyingQuarterly Risk Review & Short-Term High Return Strategies - baoquankhu1.vn
BTIG Research Reiterates "Buy" Rating for Apogee Therapeutics (NASDAQ:APGE) - MarketBeat
HighVista Strategies LLC Grows Position in Apogee Therapeutics Inc. $APGE - MarketBeat
APGEApogee Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction - AOL.com
Boxer Capital Management LLC Acquires New Holdings in Apogee Therapeutics Inc. $APGE - MarketBeat
Braidwell LP Sells 39,767 Shares of Apogee Therapeutics Inc. $APGE - MarketBeat
CEO Michael Henderson Sells 20,000 Shares of Apogee Therapeutics Inc (APGE) - GuruFocus
Apogee Therapeutics (NASDAQ:APGE) CEO Michael Thomas Henderson Sells 20,000 Shares - MarketBeat
Apogee Therapeutics CEO Sells 20,000 Shares - TradingView
Apogee Therapeutics (APGE) CEO sells 20,000 shares in pre-set 10b5-1 plan - Stock Titan
The Technical Signals Behind (APGE) That Institutions Follow - Stock Traders Daily
Barclays PLC Buys 33,494 Shares of Apogee Therapeutics Inc. $APGE - MarketBeat
A Look At Apogee Therapeutics (APGE) Valuation After Wider Losses And A New Shelf Registration - Sahm
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million - AOL.com
Wedbush Raises Price Target on Apogee Therapeutics (APGE) - Finviz
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds - Insider Monkey
Jefferies Financial Group Inc. Sells 74,273 Shares of Apogee Therapeutics Inc. $APGE - MarketBeat
RBC Capital Initiates Coverage of Apogee Therapeutics (APGE) with Outperform Recommendation - MSN
Performance Recap: What is Apogee Therapeutics Incs 5 year growth outlookJuly 2025 Pullbacks & Accurate Buy Signal Alerts - baoquankhu1.vn
Apogee Therapeutics (NASDAQ:APGE) Insider Carl Dambkowski Sells 5,500 Shares - MarketBeat
Apogee Therapeutics (APGE) CMO sells shares under 10b5-1 trading plan - Stock Titan
T. Rowe Price (APGE) holds 6.21M shares, 11.3% stake disclosed - Stock Titan
Vanguard Group Inc. Has $89.22 Million Stock Holdings in Apogee Therapeutics Inc. $APGE - MarketBeat
Rafferty Asset Management LLC Acquires 23,585 Shares of Apogee Therapeutics Inc. $APGE - MarketBeat
Apogee Therapeutics (APGE) Gets a Buy from Mizuho Securities - The Globe and Mail
Citi Remains a Buy on Apogee Therapeutics (APGE) - The Globe and Mail
CFO at Apogee Therapeutics (APGE) sells 2,000 shares in planned trades - Stock Titan
Apogee Therapeutics Teases 52-Week Zumi Durability Data, Phase III Path at TD Cowen Conference - MarketBeat
Is Rising R&D Spend And New Equity Shelf Altering The Investment Case For Apogee Therapeutics (APGE)? - Yahoo Finance
APGE: RBC Capital Lowers Price Target to $82, Maintains Sector P - GuruFocus
Apogee Therapeutics (APGE) Stock Analysis: Exploring a 47.76% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $95.00 - MarketBeat
RBC Lowers Price Target on Apogee Therapeutics to $82 From $83, Keeps Sector Perform, Speculative Risk - marketscreener.com
Apogee’s Deeper Losses and New Shelf Filing Test Its High-Risk Pipeline Strategy (APGE) - Sahm
Apogee Therapeutics Stock: Clinical-Stage Risks, Unproven Pipeline, and Uncertain Path to Profitability - TipRanks
Decoding Apogee Therapeutics Inc (APGE): A Strategic SWOT Insigh - GuruFocus
RBC Capital lowers Apogee Therapeutics stock price target on dosing outlook By Investing.com - Investing.com Australia
RBC Capital lowers Apogee Therapeutics stock price target on dosing outlook - Investing.com Australia
Key facts: Apogee Therapeutics posts $285.6M loss; plans Phase 3 trial - TradingView
APGE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Apogee Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Apogee Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Wedbush Adjusts Price Target on Apogee Therapeutics to $95 From $90, Maintains Outperform Rating - marketscreener.com
Apogee Therapeutics Inc Stock (APGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.20%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):